Urogen Pharma (NASDAQ:URGN) Given Buy Rating at D. Boral Capital

Urogen Pharma (NASDAQ:URGN)‘s stock had its “buy” rating reissued by D. Boral Capital in a research note issued on Monday,Benzinga reports. They presently have a $33.00 price objective on the stock. D. Boral Capital’s price objective points to a potential upside of 67.03% from the stock’s previous close.

A number of other brokerages have also recently commented on URGN. Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a research note on Wednesday, January 21st. Wall Street Zen upgraded shares of Urogen Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Urogen Pharma has a consensus rating of “Moderate Buy” and an average price target of $33.29.

Urogen Pharma Stock Performance

NASDAQ URGN traded down $1.94 during trading hours on Monday, hitting $19.76. 1,015,128 shares of the company traded hands, compared to its average volume of 717,665. The business’s 50-day moving average is $21.28 and its 200-day moving average is $20.89. The stock has a market capitalization of $924.81 million, a price-to-earnings ratio of -5.72 and a beta of 1.32. Urogen Pharma has a twelve month low of $3.42 and a twelve month high of $30.00.

Urogen Pharma (NASDAQ:URGN) last announced its quarterly earnings data on Monday, March 9th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.11. The company had revenue of $37.84 million for the quarter, compared to the consensus estimate of $39.92 million. Analysts predict that Urogen Pharma will post -3.12 EPS for the current year.

Insider Buying and Selling

In other news, General Counsel Jason Drew Smith sold 7,479 shares of the company’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total value of $147,261.51. Following the transaction, the general counsel owned 51,326 shares of the company’s stock, valued at approximately $1,010,608.94. This represents a 12.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Mark Schoenberg sold 7,373 shares of Urogen Pharma stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total value of $145,174.37. Following the sale, the insider directly owned 144,985 shares of the company’s stock, valued at approximately $2,854,754.65. The trade was a 4.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 4.70% of the company’s stock.

Hedge Funds Weigh In On Urogen Pharma

A number of hedge funds have recently bought and sold shares of the business. Osaic Holdings Inc. boosted its holdings in Urogen Pharma by 491.2% in the 2nd quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock valued at $50,000 after purchasing an additional 3,070 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Urogen Pharma by 27.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock valued at $53,000 after buying an additional 486 shares in the last quarter. State of Wyoming acquired a new stake in shares of Urogen Pharma in the third quarter valued at approximately $66,000. Russell Investments Group Ltd. boosted its stake in shares of Urogen Pharma by 1,594.4% in the third quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock valued at $66,000 after buying an additional 3,125 shares during the period. Finally, Strs Ohio acquired a new stake in Urogen Pharma during the third quarter worth approximately $76,000. 91.29% of the stock is owned by institutional investors.

Key Headlines Impacting Urogen Pharma

Here are the key news stories impacting Urogen Pharma this week:

• Positive Sentiment: Company says ZUSDURI™ commercial launch is on track; reported initial net sales of $15.8M in 2025 and permanent J‑code became effective Jan 1, 2026, which should streamline reimbursement and support broader access. UroGen Announces ZUSDURI Launch is On-Track
• Positive Sentiment: Q4 EPS beat: loss per share of ($0.54) topped consensus (-$0.65), signaling slightly better-than-expected profitability progress even as the company remains unprofitable. Urogen Pharma Reports Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: Refinancing announced with Pharmakon Advisors: new term‑loan structure (reported fixed ~8.25%) extends amortization to Q1 2030 and is described as meaningfully reducing cost of capital, which should ease near‑term liquidity pressure and be non‑dilutive. UroGen Announces Refinanced Term Loan Agreement
• Neutral Sentiment: Analysts maintain constructive views — recent consensus is an average “Moderate Buy” — which signals continued analyst support but not a unanimous upgrade catalyst. Urogen Pharma Given Average Rating of Moderate Buy
• Neutral Sentiment: Company held an earnings release and a conference call/webcast to discuss results and launch plans (management commentary will be important for near‑term guidance). Press Release
• Negative Sentiment: Revenue missed expectations: Q4 sales $37.84M versus consensus ~$39.92M, which likely fueled the intraday share weakness despite the EPS beat — investors focus on top‑line trajectory as the company commercializes new products. Revenue Miss Note

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.